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SHORT COMMUNICATION
Clinical measurements performed during alfaxalone total intravenous anaesthesia
(TIVA) for radiography and neurophysiological investigations in dogs
Abstract (289 words)
Objective To describe clinically relevant, physiological measurements collected during a 3-
hour duration alfaxalone total intravenous anaesthesia.
Study design Case series.
Animals A total of 112 client-owned middle aged or older dogs.
Methods Dogs were premedicated with intramuscular acepromazine (0.03 mg kg-1).
Anaesthesia was induced and subsequently maintained for up to 3 hours with alfaxalone
administered intravenously. Dogs breathed 100% oxygen via an endotracheal tube. Heart
rate, respiratory rate, and blood pressure were evaluated 30 minutes after administration of
acepromazine and used as baseline values for comparisons of intra-anaesthetic data. Blood
glucose was measured one week prior to anaesthesia and every hour during alfaxalone
anaesthesia. Quality and duration of recovery were recorded. Mean data for physiological
variables were compared over three time points; before induction of anaesthesia, forthe first
hour of anaesthesia and from 60 minutes to discontinuation of anaesthesia.
Results Mean induction dose of alfaxalone was 1.4 (95% CI 1.3 - 1.5) mg kg-1. Post induction
apnoea for greater than 60 seconds occurred in 13 (11.6%) dogs. Mean alfaxalone infusion
rate during the first 60 minutes of anaesthesia was 0.099 mg kg-1 minute-1; from 60 minutes
until discontinuation of anaesthesia, mean infusion rate was 0.092 mg kg-1 minute-1.
Heart rate was well maintained; hypotension (mean arterial blood pressure < 60 mmHg) was
encountered in 23 (21%) of dogs. Blood glucose levels did not alter during anaesthesia.
Median time between discontinuation of alfaxalone infusion and extubation was 17 (7 - 35
minutes), time to assuming sternal recumbency was 75 (58 - 110 minutes), and time to
standing was 109 (88 - 140 minutes).
Conclusions and clinical relevance. Alfaxalone infusion provided effective anaesthesia in
this population. In a minority of cases respiratory and haemodynamic support of the patient
was required.
Keywords Alfaxalone, Dog, Total Intravenous Anaesthesia
Introduction
Alfaxalone solubilised in 2- hydroxypropyl-β-cyclodextrin (HPCD) is licensed for use in 
dogs for induction and maintenance of anaesthesia by Continuous Rate Infusion (CRI). The
use of alfaxalone as an intravenous induction agent has not demonstrated any significant
effects on blood glucose concentration (Muñoz et al. 2017), and HPCD is reported to be
largely renally excreted, without undergoing significant amylase catalysed degradation to
glucose (Irie & Uekama 1997). However, it is possible that exposure to the carrier for some
hours during total intravenous anaesthesia could produce alteration in serum glucose
concentrations. The effect of a CRI of alfaxalone in HPCD on serum glucose measurements
has not knowingly been previously reported in dogs.
The objectives of the study were as follows: We aimed to report routinely measured clinical
physiological parameters during the anaesthetic episode, and to measure glucose
concentrations hourly during the alfaxalone infusion. We hypothesised that the qualities of
anaesthesia in this population of dogs would reflect previously described findings of
hypoventilation and mild haemodynamic changes (Ambros et al. 2008; Suarez et al. 2012;
Herbert et al. 2013), and that alfaxalone infusion would have no significant effect on serum
glucose concentrations.
Materials and methods
Ethics
The study was conducted under the terms of the Animal (Scientific Procedures) Act, 1986 (as
amended, 2013).
Recruitment criteria
Dogs with osteoarthritis and a healthy control group were recruited to the study. Dogs were
healthy (American Society of Anesthesiologists grade I/II) on the basis of preanaesthetic
physical examination and routine biochemistry and haematology prior to anaesthesia. For the
osteoarthritis group suitable dogs were 12 kg bodyweight and over, of any age, body
condition and sex exhibiting suspected painful uni- or bilateral coxofemoral or stifle
degenerative joint disease (DJD) as evidenced by lameness/stiffness/difficulty rising or
ascending steps. Dogs with primarily forelimb lameness were excluded. For the control
group, dogs were 6 years old or greater and 12 kg bodyweight and over, exhibiting no
evidence of lameness or stiffness and with no other painful condition (e.g. otitis externa) and
no previous diagnosis of OA. We aimed to recruit 100 dogs with OA and 35 control dogs
based on a sample size calculation associated with the primary reason to perform the study
(i.e. measurement of nociceptive withdrawal reflexes in dogs).
Study protocol
Owners of eligible dogs were asked to attend with their dog for a screening appointment, at
which signed consent to participate was obtained. Jugular vein blood samples were collected
and submitted for biochemistry and haematology, and whole blood glucose measurement was
performed using a handheld device (Alphatrak 2; Abbott Diabetes Care Inc., CA, USA)
validated for measurement of glucose concentrations in canine blood.
Premedication and preanaesthetic measurements
Seven days after the screening appointment, dogs were admitted in order to undergo
radiography and Nociceptive Withdrawal Reflex (NWR) testing under general anaesthesia.
Food was withheld for 8 hours prior to anaesthesia. Acepromazine (0.03mg kg-1) (ACP 2mg
mL-1 solution; Elanco Animal Health, Basingstoke, UK) was administered into the cervical
epaxial muscles, and dogs were left undisturbed for 30 minutes, following which a cephalic
venous catheter was placed. Indirect oscillometric (Datex-Ohmeda S5) systolic (S), diastolic
(D), and mean (M) arterial pressure (AP) was determined using a cuff width of 30-40% limb
circumference with the dog in lateral recumbency, using the dorsal pedal arterial site. Heart
(HR) and respiratory rate (fR) were assessed manually and recorded prior to induction of
anaesthesia.
Anaesthesia
Alfaxalone [Alfaxan, Jurox (UK) Ltd, Crawley, UK) (1-2 mg kg-1)] was administered
intravenously over 60 seconds until orotracheal intubation was possible. Oxygen was
administered via a circle breathing system and anaesthesia maintained using an infusion
pump with a constant rate infusion of alfaxalone (initially 0.1 mg kg-1 minute-1) during
radiography, reducing to/span>(initially) 0.09 mg kg-1 minute-1 for NWR testing. Adjustments
were made to infusion rates to produce a clinically determined minimal anaesthetic state
required for the procedure. It was important that dogs did not exhibit voluntary movement
during the procedure, but a slight palpebral reflex was maintained. During anaesthesia dogs
were constantly monitored by a trained research technician and a multiparameter monitor
(Datex-Ohmeda S5; GE Medical Systems Ltd, UK) was used to measure HR, fR, SAP, MAP,
DAP, end-tidal carbon dioxide (PE′CO2), and haemoglobin oxygen saturation (SpO2).
Hypoventilation (PE′CO2 > 8 kPa recorded for at least 2 measurements) was managed by
manually ventilating the lungs until PE′CO2 < 6.7 kPa for 60 seconds and decreasing the rate
of alfaxalone infusion if possible. Hypotension was defined as a MAP < 60 mmHg and was
managed with a bolus of Hartmann’s solution 5 mL kg-1 intravenously.
Values for the monitored parameters were recorded at 5 minute intervals throughout the
duration of anaesthesia. Blood glucose was measured hourly during anaesthesia using a hand-
held blood glucose monitor calibrated for dogs (Alphatrak 2; Abbott Diabetes Care Inc., CA,
USA) starting immediately after induction of anaesthesia. Blood for glucose measurement
was collected from the left or right ear pinnae using a needle prick. Rectal temperature was
monitored every 30 minutes and supported with insulated electric blankets. Hartmann’s
solution (Aquapharm no. 11; Animalcare, UK) was infused at a rate of 5 mL kg-1 hour-1
throughout anaesthesia.
Radiography and Nociceptive Withdrawal Reflex (NWR) testing
Radiography of the hindlimbs was performed over approximately 60 minutes. Dogs were
positioned in left lateral recumbency for NWR testing and the protocol was performed as
previously described (Hunt et al. 2016). Following NWR testing, the alfaxalone infusion was
discontinued and the dogs constantly monitored. Recovery quality was scored using a simple
descriptive scale (SDS) from 0 (poor) to 3 (excellent) (Hunt et al. 2014).
Statistical methods
Descriptive statistics were used to define the population studied. Raw data for physiological
variables were plotted, and there appeared to be a change in recorded values at 60 minutes
following induction, with a decrease in HR and increase in PE′CO2 noted. Summary measures
(mean values) were thus calculated for physiological parameters for each dog from 0-60
minutes of anaesthesia, and from 60 minutes until discontinuation of anaesthesia, to produce
three separate time periods for comparison; preanaesthesia (baseline), 0-60 minutes of
anaesthesia, and from 60 minutes until discontinuation of anaesthesia. Physiological data
were assessed using the Friedman test for repeated measures, followed by Dunn’s multiple
comarison post-hoc testing, to evaluate differences between time periods. Comparisons
between paired data collected during two time periods only (e.g. PE′CO2, SpO2) were
performed using Wilcoxon’s signed rank test. Descriptive and physiological parameter data
are presented as mean (95% CI), whilst SDS data are presented as median (25-75th percentile)
Results
Demographics
A total of 112 dogs completed anaesthesia out of 114 dogs eligible for the study.
Mean age was 9.2 (95% CI 8.8 - 9.7) years and weight was 26.7 (95% CI 24.9 - 28.4) kg.
Body condition score was a median of 5 (4-6). In total 10 male, 7 female, 43 male neutered,
and 52 female neutered dogs completed anaesthesia. Mean induction dose of alfaxalone was
1.4 (95% CI 1.3 - 1.5) mg kg-1.
Post-induction apnoea
Dogs which did not initiate spontaneous respiration within 60 seconds of induction of
anaesthesia were administered manual ventilation at a rate of 4 breaths minute-1, until
spontaneous ventilation resumed. Thirteen (11.6%) dogs required ventilation, for 3.5 (95% CI
3.3-3.6) minutes.
Duration of anaesthesia was 165 (150-195) minutes. The alfaxalone infusion rate during the
first 60 minutes of anaesthesia was 0.1 (95% CI 0.09 - 0.1) mg kg-1 minute-1; from 60 minutes
until discontinuation of anaesthesia, the infusion rate was 0.1 (95% CI 0.08 - 0.09) mg kg-1
minute-1.
Heart rate
Heart rate (Table 1) was significantly elevated [114 (95% CI 111 – 118) beats minute-1 ; p <
0.001] during 0-60 minutes of anaesthesia compared with both baseline [98 (95% CI 94 – 103
beats minute-1)] and the second hour of anaesthesia [98 (95% CI 94 – 101 beats minute-1)].
Arterial blood pressure
Systolic, mean, and diastolic arterial blood pressure (Table 1) were significantly decreased
during both time periods of alfaxalone anaesthesia, compared with baseline values, however,
blood pressure was within physiological limits in the majority of animals. In 23 dogs (21%) a
hypotension was recorded on at least 2 occasions during the first 60 minutes of anaesthesia,
but only 9 dogs (8%) exhibited hypotension during anaesthesia from 60 minutes to
discontinuation.
Respiratory rate
Frequency of respiration was significantly decreased during both time periods of alfaxalone
anaesthesia; 11 (95% CI 10 - 12) breaths minute-1 and 12 (95% CI 11 - 14) breaths minute-1,
compared with preanaesthetic values of 22 (95% CI 21 - 23) breaths minute-1 (Table 1).
End-tidal carbon dioxide and haemoglobin oxygen saturation
During the first 60 minutes of anaesthesia, the PE′CO2 was 6 (95% CI 5.7 – 6.2) kPa, and
significantly increased during the second hour of anaesthesia to 6.4 (95% CI 6.1 – 6.7) kPa; p
< 0.001. Hypoventilation was identified in 18 dogs (16%).
Glucose
Serum glucose concentration immediately following anaesthetic induction was 6.7 (95% CI
6.5-6.9) mmol L-1 which was significantly higher than at initial examination [5.8 (95% CI 5.6-
6.0) mmol L-1; p < 0.001], but during anaesthesia serum blood glucose remained stable,
compared with values immediately following induction {1 hour [6.9 (95% CI 6.6 – 7.1)
mmol L-1]; 2 hours [6.9 (95% CI 6.6 – 7.1) mmol L-1]; p = 0.37).
Recovery
Median time between discontinuation of alfaxalone infusion and extubation, following the
return of pharyngeal reflexes, was 17 (7 – 35) minutes. Time to assuming sternal recumbency
was 75 (58 – 110) minutes, and time to standing was 109 (88 – 140) minutes. Recovery
quality was good, with a SDS of 2 (2 – 3).
Discussion
This prospective study demonstrates that an alfaxalone CRI provided effective anaesthetic
maintenance to enable positioning for radiography, and for completion of a
neurophysiological study in this population of client owned dogs, accompanied by similar
physiological changes to those expected from previous research studies (Ambros et al. 2008;
Suarez et al. 2012; Herbert et al. 2013).
Arterial blood pressure was decreased, compared with sedated, baseline values, whilst HR
was increased during the first hour of anaesthesia. Other research has reported increases in
HR following induction of anaesthesia with alfaxalone, and it has been suggested that
alfaxalone may better preserve baroreceptor function compared with propofol (Amengual et
al. 2012).
Serum glucose concentration measured from ear capillary blood was found to be higher
immediately following induction of anaesthesia, compared with a baseline measurement from
a jugular vein blood sample one week prior to anaesthesia. It is most likely that anxiety,
administration of premedicants and cephalic venous catherisation prompted sympathetically
mediated increases in glucagon and adrenaline, and decreases in insulin secretion; i.e. the
increase in blood glucose concentration was likely promoted by a stress response to
anaesthesia, including the administration of alfaxalone. The site of blood sampling may be
expected to affect whole blood glucose concentrations, with arterial and capillary samples
producing higher estimations compared to venous blood (Cengiz & Tamborlane 2009), and
this may also have contributed to the apparent significant increase in glucose concentration
between the screening appointment and anaesthesia. Despite changes from the screening
appointment, glucose concentrations were stable throughout the period of anaesthesia,
suggesting that HPCD neither significantly binds glucose, nor undergoes hydrolysis during
CRI over a duration of 3 hours in the dog.
In conclusion, alfaxalone CRI at a rate of 0.09-0.1 mg kg-1 minute-1 produced stable
anaesthesia for radiography and neurophysiological experiments in middle aged to older dogs
with minimal clinically significant haemodynamic changes but was accompanied by
respiratory depression. Endotracheal intubation and a means to deliver mechanical ventilation
are essential for the safe use of the agent.
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Table 1 Physiological measures compared over time in dogs premedicated with
acepromazine and induced with intravenous alfaxalone and maintained with an intravenous
alfaxalone continuous rate infusion. Data are reported as mean (95% CI).
Variable Preanaesthetic Anaesthesia 0-
60 minutes
Anaesthesia 60
minutes -
discontinuation
p
HR (beats
minute-1)
98 (95% CI 94-
103)a
114 (95% CI
111-118)b
98 (95% CI 94 –
101)a
<0.001***
fR
(breaths
minute-1)
22 (95% CI 21-
23)a
11 (95% CI 10-
12)b
12 (95% CI 11-
14)b
<0.001***
SAP
(mmHg)
128 (95% CI
122-133)a
109 (95% CI
106-111)b
112 (95% CI 109-
114)b
<0.001***
MAP
(mmHg)
100 (95% CI 95
– 105)a
83 (95% CI 81-
85)b
82 (95% CI 80-
84)b
<0.001***
DAP
(mmHg)
81 (95% CI 76-
86)a
66 (95% CI 63-
68)b
63 (95% CI 61-
66)b
<0.001***
PE′CO2
(kPa)
- 6 (95% CI 5.7-
6.2)
6.4 (95% CI 6.1-
6.7)
<0.001***
SpO2
(%)
- 98 (95% CI 97-
98)
99 (95% CI 99-
99)
<0.001***
Rectal
Temperature
oC
38.3 (95% CI
38.1 – 38.5)a
37.6 (95% CI
37.5 – 37.7)b
37.5 (95% CI
37.4 – 37.7)b
<0.001***
Superscript letters indicate groupings within the data, shared superscripts indicate no
significant difference between groups on post-hoc testing, differing superscripts indicate a
difference with a p value of less than 0.05 on post-hoc testing. * p ≤ 0.05; ** p ≤ 0.01; *** p
≤ 0.001  
